D3821

Devazepide

≥98% (HPLC), powder

• 동의어(들): (S)-N-(2,3-Dihydro-1-methyl-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)indole-2-carboxamide, L-364,718, MK 329
• 실험식(Hill 표기법): C₂₅H₂₀N₄O₂
• CAS Number: 103420-77-5
• Molecular Weight: 408.45
• MDL number: MFCD00864500
• UNSPSC 코드: 12352200
• PubChem Substance ID: 329798778
• NACRES: NA.77

속성

• Quality Level: 100
• 분석: ≥98% (HPLC)
• 양식: powder
• 저장 조건: desiccated
• 색상: white to off-white
• solubility: DMSO: >5 mg/mL
• 주관자: Merck & Co., Inc., Kenilworth, NJ, U.S.
• 저장 온도: 2-8°C
• SMILES string: CN1C(=O)[C@@H](NC(=O)c2cc3ccccc3[nH]2)N=C(c4ccccc4)c5ccccc15
• InChI: 1S/C25H20N4O2/c1-29-21-14-8-6-12-18(21)22(16-9-3-2-4-10-16)27-23(25(29)31)28-24(30)20-15-17-11-5-7-13-19(17)26-20/h2-15,23,26H,1H3,(H,28,30)/t23-/m1/s1
• InChI key: NFHRQQKPEBFUJK-HSZRJFAPSA-N

설명

일반 설명

Devazepide is derived from asperlicin by chemical modification and has the benzodiazepine backbone.

애플리케이션

Devazepide has been used as a cholecystokinin receptor 1 (CCK1R) antagonist in human embryonic kidney 293T cells and in human pancreatic slices.

생화학적/생리학적 작용

Devazepide is a CCK1 (CCK-A) receptor antagonist and a CCK8 antagonist.

Devazepide is a CCK1 receptor antagonist.

Devazepide is a cholecystokinin octapeptide (CCK1) (CCK-A) receptor antagonist. It inhibits CCK binding to peripheral-type receptor (CCK-A). Devazepide reverses the cholecystokinin octapeptide (CCK-8) based antagonism towards morphine.

특징 및 장점

This compound was developed by Merck & Co., Inc., Kenilworth, NJ, U.S.. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

안전성 정보

• 픽토그램: GHS06
• 신호어: Danger
• 유해 및 위험 성명서: H300
• 예방조치 성명서: P264 - P270 - P301 + P310 - P405 - P501
• Hazard Classifications: Acute Tox. 1 Oral
• Storage Class Code: 6.1A - Combustible acute toxic Cat. 1 and 2 / very toxic hazardous materials
• WGK: WGK 3
• Flash Point (°F): Not applicable
• Flash Point (°C): Not applicable